Sanofi, AstraZeneca win US approval for RSV therapy …
WEBStory by Reuters. • 8m. (Reuters) -Sanofi and partner AstraZeneca have received approval from the U.S. Food and Drug Administration for a manufacturing line for their preventive respiratory ...
Press Room - Sanofi US News
WEBSep 11, 2024 · If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S. and European Union. Paris and Tarrytown, NY, September 11, 2024. A Dupixent (dupilumab) pivotal study (ADEPT) in bullous pemphigoid (BP) met the primary and all key secondary endpoints evaluating its investigational use in adults with …
Sanofi Teams Up With RadioMedix, Orano in $352 Mln Deal for …
WEB6 days ago · Sanofi agreed to pay up to 320 million euros ($352.4 million) to U.S. company RadioMedix and the biotechnology subsidiary of nuclear-fuel supplier Orano to license a potential treatment for rare ...
Latest Sanofi Press Releases and News | Sanofi
WEBAug 26, 2024 · Stay informed with the latest Sanofi press releases and news updates. Discover new developments in healthcare and pharmaceuticals with Sanofi.
Sanofi pushes ahead with €20bn consumer healthcare spin-off
WEBJun 2, 2024 · The move makes Sanofi the latest Big Pharma company to seek to separate low-margin, consumer businesses from divisions focused on innovative new medicines that offer higher returns.
Press Room - Sanofi US News
WEBMay 31, 2024 · Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical studies involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.
Sanofi Pipeline Transformation to Accelerate Growth Driven by …
WEBDec 7, 2002 · Sanofi’s R&D will lead to a 50% increase in the number of Phase 3 studies between 2023 and 2025, creating the greatest pipeline momentum in Sanofi’s history. The company’s commitment to R&D will also support an expected 25 mid- to late-stage read-outs and up to 19 regulatory submissions for its pharma assets in the next two years.
Sanofi Enters Next Chapter of Play to Win Strategy | Sanofi
WEBOct 27, 2005 · Sanofi today provided a comprehensive update regarding its Play to Win strategy. This strategy continues to focus on the critical goals of executing transformative medicine and vaccines launches, driving agile and efficient resource deployment and enhancing R&D productivity.
Sanofi readies to meet US demand for RSV antibody - Yahoo …
WEB3 days ago · In this article: Sanofi said it’s ready to meet demand for its RSV shot Beyfortus this year, announcing Monday the clearance by the Food and Drug Administration of a new manufacturing line. The ...
Sanofi shipping BEYFORTUS® in US to help protect babies …
WEB2 days ago · Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements ...